CHAMPIONS ONCOLOGY, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $11.96 per share for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-07-27
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2022-07-31 was $5.40.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2021-07-31 was $0.00.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2019-07-31 was $12.24.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2018-07-31 was $0.00.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2026 was $11.96, a 120.26% increase from fiscal 2025.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $5.43, a 57.51% decline from fiscal 2024.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $12.78, a 136.67% increase from fiscal 2023.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $5.40, a 43.75% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-04-30 | $11.96 10-K · filed 2026-07-27 | ||||
| 2025-04-30 | $5.43 10-K · filed 2025-07-23 | ||||
| 2024-04-30 | $12.78 10-K · filed 2025-07-23 | ||||
| 2023-04-30 | $5.40 10-K · filed 2024-07-19 | ||||
| 2023-01-31 | $5.40 10-Q · filed 2023-03-16 | ||||
| 2022-10-31 | $5.40 10-Q · filed 2022-12-13 | ||||
| 2022-07-31 | $5.40 10-Q · filed 2022-09-12 | ||||
| 2022-04-30 | $9.60 10-K · filed 2023-07-24 | ||||
| 2022-01-31 | $9.60 10-Q · filed 2022-03-15 | ||||
| 2021-10-31 | $9.60 10-Q · filed 2021-12-13 | ||||
| 2021-07-31 | $0.00 10-Q · filed 2021-09-13 | ||||
| 2021-04-30 | $10.80 10-K · filed 2022-07-22 | ||||
| 2021-01-31 | $10.80 10-Q · filed 2021-03-15 | ||||
| 2020-10-31 | $10.80 10-Q · filed 2020-12-14 | ||||
| 2020-04-30 | $8.04 10-K · filed 2021-07-26 | ||||
| 2020-01-31 | $8.04 10-Q · filed 2020-03-16 | ||||
| 2019-10-31 | $8.04 10-Q · filed 2019-12-16 | ||||
| 2019-07-31 | $12.24 10-Q · filed 2019-09-16 | ||||
| 2019-04-30 | $15.10 10-K · filed 2020-07-28 | ||||
| 2019-01-31 | $0.00 10-Q · filed 2019-03-18 | ||||
| 2018-10-31 | $0.00 10-Q · filed 2018-12-17 | ||||
| 2018-07-31 | $0.00 10-Q · filed 2018-09-14 | ||||
| 2018-04-30 | $5.21 10-K · filed 2019-07-29 | ||||
| 2018-01-31 | $5.21 10-Q · filed 2018-03-19 | ||||
| 2017-10-31 | $8.44 10-Q · filed 2017-12-15 | ||||
| 2017-07-31 | $0.00 10-Q · filed 2017-09-14 | ||||
| 2017-04-30 | $7.86 10-K · filed 2018-07-30 | ||||
| 2017-01-31 | $7.86 10-Q · filed 2017-03-17 | ||||
| 2016-10-31 | $7.34 10-Q · filed 2016-12-14 | ||||
| 2016-07-31 | $10.64 10-Q · filed 2016-09-14 | ||||
| 2016-04-30 | $6.97 10-K · filed 2017-07-28 | ||||
| 2016-01-31 | $6.91 10-Q · filed 2016-03-16 | ||||
| 2015-10-31 | $6.80 10-Q · filed 2015-12-15 | ||||
| 2015-07-31 | $9.24 10-Q · filed 2015-09-11 | ||||
| 2015-04-30 | $11.88 10-K · filed 2016-07-29 | $0.99 10-K · filed 2015-07-29 | |||
| 2015-01-31 | $1.04 10-Q · filed 2015-03-17 | ||||
| 2014-10-31 | $1.12 10-Q · filed 2014-12-15 | ||||
| 2014-07-31 | $1.12 10-Q · filed 2014-09-12 | ||||
| 2014-04-30 | $0.73 10-K · filed 2015-07-29 | ||||
| 2014-01-31 | $0.75 10-Q · filed 2014-03-14 | ||||
| 2013-10-31 | $0.75 10-Q · filed 2013-12-13 | ||||
| 2013-07-31 | $0.75 10-Q · filed 2013-09-13 | ||||
| 2013-04-30 | $0.95 10-K · filed 2014-07-28 | ||||
| 2013-01-31 | $0.76 10-Q · filed 2013-03-13 | ||||
| 2012-04-30 | $0.60 10-K · filed 2013-07-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |